首页> 美国卫生研究院文献>The World Allergy Organization Journal >Asthma Treatment: 188 Efficacy Comparison of Mometasone Furoate/Formoterol Versus Fluticasone Propionate/Salmeterol Combination Therapies in Subjects With Persistent Asthma: Noninferiority and Onset-of-Action Findings
【2h】

Asthma Treatment: 188 Efficacy Comparison of Mometasone Furoate/Formoterol Versus Fluticasone Propionate/Salmeterol Combination Therapies in Subjects With Persistent Asthma: Noninferiority and Onset-of-Action Findings

机译:哮喘治疗:糠酸莫米松/福莫特罗与丙酸氟替卡松/沙美特罗联合治疗对持续性哮喘患者的疗效比较188:非劣效性和开始行动的结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMometasone furoate/formoterol (MF/F) combination therapy is a new treatment recently approved by the US Food and Drug Administration for the treatment of persistent asthma and currently under regulatory review by Canadian authorities. We report findings from a noninferiority study that compared effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma.
机译:背景糠酸莫米他松/福莫特罗(MF / F)联合疗法是美国食品和药物管理局最近批准的用于治疗持续性哮喘的新疗法,目前正受到加拿大当局的监管审查。我们报告了一项非劣效性研究的结果,该研究比较了MF / F和丙酸氟替卡松/沙美特罗(FP / S)联合疗法对持续性哮喘患者肺功能和起效的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号